Trial Outcomes & Findings for Docetaxel and Epirubicin in Advanced Gastric Cancer (NCT NCT00375999)

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

34 participants

Primary outcome timeframe

One year

Results posted on

2014-03-03

Participant milestones
Measure	Treatment Group Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer
Overall Study STARTED	34
Overall Study COMPLETED	32
Overall Study NOT COMPLETED	2

Withdrawal data not reported

Docetaxel and Epirubicin in Advanced Gastric Cancer

Baseline characteristics by cohort
Measure	Treatment Group n=34 Participants Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer
Age, Continuous	53 years n=5 Participants
Sex: Female, Male Female	10 Participants n=5 Participants
Sex: Female, Male Male	24 Participants n=5 Participants
Region of Enrollment Korea, Republic of	34 participants n=5 Participants

Timeframe: One year

Outcome measures
Measure	Treatment Group n=32 Participants Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer
Overall Survival	13.4 month Interval 7.0 to 19.8

Serious events: 3 serious events

Other events: 16 other events

Deaths: 0 deaths

Serious adverse events
Measure	Treatment Group n=34 participants at risk Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer
Infections and infestations sepsis	2.9% 1/34
Respiratory, thoracic and mediastinal disorders pneumonia	5.9% 2/34

Other adverse events
Measure	Treatment Group n=34 participants at risk Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer
Blood and lymphatic system disorders neutropenia	47.1% 16/34 • Number of events 16

Gangnam Severance Hospital, Yonsei University College of Medicine

Phone: 82-2-2019-4363